EPAS1 and paraganglioma: Among the EPAS1 mutation-positive tumour samples (phaeochromocytomas, n = 7; paragangliomas, n = 1), 37.5% showed no change or low expression and 62.5% of samples had high EPAS1 protein expression (Figure 1).